Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.56 |
| ▸ | LAP3 | P28838 | 7/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.55 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10772763 | 1.00 | SLC15A1 (0.56) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL4619659 | 1.00 | SLC15A1 (0.56) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL6342154 | 1.00 | SLC15A1 (0.56) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL9515701 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL6348571 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL21854197 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL540968 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL10775336 | 0.98 | SLC15A1 (0.54) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL7698421 | 0.86 | ALPI (0.62) | SLC15A1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL2029167 | 0.86 | ALPI (0.62) | SLC15A1LAP3ANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563033-B | Aliphatic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7276500-B2 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO. KG (DE) | 2007-10-02 | — | — | US | disclosed |
| US-6753327-B1 | NEURODEGENERATIVE DISORDER OR NEURONAL DAMAGE TREATMENT; INHIBITORS OF CALPAIN OR CATHEPSIN CYSTEINE PROTEASES; ANTIISCHEMIC AGENTS; REPERFUSION INJURIES | ABBOTT GMBH & CO. KG (DE) | 2004-06-22 | — | — | US | disclosed |
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | ABBOTT GMBH & CO., KG | 2004-04-29 | — | — | US | disclosed |
| US-6380220-B1 | THERAPY OF NEURODEGENERATIVE DISEASES AND NEURONAL INJURIES WHICH ARE CASUED BY ISCHEMIA, TRAUMA OR MASSIVE HEMORRHAGES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| US-5952328-A | MAY BE USED TO ALLEVIATE, MEDIATE, REDUCE AND/OR PREVENT DISORDERS WHICH ARE ASSOCIATED WITH ABNORMAL AND/OR ABERRANT ACTIVITY OF CYSTEINE PROTEASES AND/OR SERINE PROTEASES | CEPHALON, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-4668769-A | Oxa- and azahomocyclostatine polypeptides | PFIZER INC. | 1987-05-26 | — | — | US | disclosed |
| EP-0211580-A2 | Renin inhibiting polypeptides and intermediates therefor | PFIZER INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| US-4599198-A | Intermediates in polypeptide synthesis | PFIZER INC. (US) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | SLC15A1 2937/4885LAP3 344/4885ANPEP 215/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | SLC15A1 3674/4885LAP3 734/4885ANPEP 696/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | SLC15A1 4187/4885LAP3 1463/4885ANPEP 1311/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | SLC15A1 3674/4885LAP3 734/4885ANPEP 696/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | SLC15A1 3674/4885LAP3 734/4885ANPEP 696/4885 |
| US-20040082569-A1 | Calcium channel blockers; cardiovascular disorders; antiarthritic agents | CACNA1C, CACNA1E, RYR1 | SLC15A1 1041/4885LAP3 4174/4885ANPEP 4703/4885 |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK4, CAMK2A, CAMK2B | SLC15A1 3658/4885LAP3 325/4885ANPEP 1132/4885 |
| US-20080113989-A1 | For example, N-(1-Carbamoyl-1-oxo-3-phenylpropan-2-yl)-2-(E-2-(4-(1-pyrrolidinylmethyl)phenyl)ethen-1-yl)benzamide; calcium channel blockers; cardiovascular disorders; antiarthritic agents; inhibitors of enzymes, especially cysteine proteases such as calpain and cathepsins | CAPN1, CAPNS1, CAPN2 | SLC15A1 669/4885LAP3 171/4885ANPEP 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.